Global and India Endogenous Peptide Substances Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global and India Endogenous Peptide Substances Market Report & Forecast 2024-2034
The global Endogenous Peptide Substances revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2033 with a CAGR of % during the review period (2023-2033).
In India, the Endogenous Peptide Substances revenue is expected to grow from US$ million in 2022 to US$ million by 2033, at a CAGR of % during the forecast period 2023-2033.
The driving force of endogenous peptides mainly comes from the following aspects
Biological functions of bioactive peptidesBioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and developmentWith the development of medical technology, people's demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technologySince the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indicationsAs the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
This report focuses on global and India Endogenous Peptide Substances market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2023, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Endogenous Peptide Substances will continue to grow rapidly in the future.
Global Endogenous Peptide Substances Scope and Market Size
Endogenous Peptide Substances market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Endogenous Peptide Substances market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2033.
For India market, this report focuses on the Endogenous Peptide Substances market size by players, by Type and by Application, for the period 2018-2033. The key players include the global and local players, which play important roles in India.
Assertio Therapeutics Inc.
Cipher Pharmaceuticals Inc.
Endo International Plc
Biosynth Carbosynth
Lannett Co. Inc.
Pfizer
Johnson & Johnson
Peptide Institute
Abbexa
Phoenix Pharmaceuticals
Creative Peptides
Segment by Type
Neuropeptides
Hormones
Cytokines
Peptide Hormones
Bioactive Peptides
Research
Medicine
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Endogenous Peptide Substances definition, global market size, India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Endogenous Peptide Substances companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Endogenous Peptide Substances in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Endogenous Peptide Substances revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
In India, the Endogenous Peptide Substances revenue is expected to grow from US$ million in 2022 to US$ million by 2033, at a CAGR of % during the forecast period 2023-2033.
The driving force of endogenous peptides mainly comes from the following aspects
Biological functions of bioactive peptidesBioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and developmentWith the development of medical technology, people's demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technologySince the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indicationsAs the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
This report focuses on global and India Endogenous Peptide Substances market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2023, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Endogenous Peptide Substances will continue to grow rapidly in the future.
Global Endogenous Peptide Substances Scope and Market Size
Endogenous Peptide Substances market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Endogenous Peptide Substances market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2033.
For India market, this report focuses on the Endogenous Peptide Substances market size by players, by Type and by Application, for the period 2018-2033. The key players include the global and local players, which play important roles in India.
By Company
Assertio Therapeutics Inc.
Cipher Pharmaceuticals Inc.
Endo International Plc
Biosynth Carbosynth
Lannett Co. Inc.
Pfizer
Johnson & Johnson
Peptide Institute
Abbexa
Phoenix Pharmaceuticals
Creative Peptides
Segment by Type
Neuropeptides
Hormones
Cytokines
Peptide Hormones
Bioactive Peptides
Segment by Application
Research
Medicine
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Endogenous Peptide Substances definition, global market size, India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Endogenous Peptide Substances companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Endogenous Peptide Substances in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Endogenous Peptide Substances revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices